The US Preventive Services Task Force reviewed the evidence on screening and treatment of vitamin-D deficiency among community-dwelling, non-pregnant adults, aged 18 years and older without symptoms of vitamin-D deficiency or conditions for which vitamin-D treatment is recommended. Among this population, the Task Force concluded that there is insufficient evidence to screen for vitamin-D deficiency. The authors explained the rational of this statement by the lack of consensus on which cut-point for 25-hydroxyvitamin-D status is used (20 ng ml À 1 versus 30 ng ml Earlier, the US Preventive Services Task Force also published recommendations on the use of vitamin-D supplementation for fall (2012) 2 and primary fracture (2013) 3 prevention. They found that vitamin-D supplementation is effective in preventing falls in community-dwelling adults aged 65 years or older who are at an increased risk for falls. 2 For the primary prevention of fractures, the US Preventive Services Task Force concluded that current evidence is insufficient for daily supplementation with vitamin-D with or without calcium supplementation among non-institutionalized or community-dwelling asymptomatic adults without a history of fractures, excluding patients with osteoporosis or individuals with vitamin-D deficiency. Addressing the same population, however, the Institute of Medicine (IOM) set in 2010 a recommended dietary allowance for vitamin-D largely based on bone health. 4 Without prior 25-hydrocyvitamin-D measurement and assuming minimal sun exposure, the IOM intake recommendation is 600 IU per day for adults aged 19-70 years and 800 IU per day for adults older than 70 years, consistent with the US Endocrine Society Task Force Recommendations on vitamin-D.
In summary, the new recommendations of the US Preventive Services Task Force against universal screening of vitamin-D deficiency among healthy adults is in line with prior recommendations.
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